Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Eur J Heart Fail. 2019 Feb 18;21(4):462–470. doi: 10.1002/ejhf.1424

Figure 2.

Figure 2.

6-year Kaplan-Meier event rates and adjusted risk of CV death or heart failure hospitalization in patients in the placebo arm stratified by Klotho and FGF-23 concentrations. As compared to Klotho Q4/FGF23 Q1–3 as the referent, the adjusted risk for CV death or heart failure hospitalization was HRadj 1.08 (95% CI 0.31–3.83) for Klotho Q4/FGF23 Q4, HRadj 2.03 (95% CI 0.88–4.66) for Klotho Q1–3/FGF23 Q1–3, and HRadj 3.99 (95% CI 1.67–9.56) for Klotho Q1–3/FGF23 Q4. Adjustment covariates: age, sex, current smoker, HTN, T2DM, prior MI, prior revascularization, weight, SBP, LVEF, eGFR, cystatin-C, UACR, NT-proBNP, hsTnT, and hsCRP.